Literature DB >> 8082414

Phagocyte transport as mechanism for enhanced therapeutic activity of liposomal amphotericin B.

R T Mehta1, T J McQueen, A Keyhani, G López-Berestein.   

Abstract

Liposomal amphotericin B (L-AmB) is emerging as one of the most attractive new antifungal agents. We have attempted to show that phagocytic cells circulating in blood play an important role in transport and accumulation of L-AmB at inflammatory sites in vivo. Free AmB or L-AmB was injected intravenously to mice, and the amount of AmB in peritoneal exudate cells was quantitated by high-performance liquid chromatography. Higher levels of AmB were detected in a higher number of mice injected with L-AmB. The presence of L-AmB in inflammatory peritoneal cells after intravenous administration of fluorescence-labeled L-AmB also suggested that macrophages play an important role in the transport of intravenously administered L-AmB to inflammatory sites.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 8082414     DOI: 10.1159/000239202

Source DB:  PubMed          Journal:  Chemotherapy        ISSN: 0009-3157            Impact factor:   2.544


  14 in total

Review 1.  Mechanisms of antimicrobial-induced nephrotoxicity in children.

Authors:  Kevin J Downes; Molly Hayes; Julie C Fitzgerald; Gwendolyn M Pais; Jiajun Liu; Nicole R Zane; Stuart L Goldstein; Marc H Scheetz; Athena F Zuppa
Journal:  J Antimicrob Chemother       Date:  2020-01-01       Impact factor: 5.790

2.  Enhanced intramacrophage activity of resorcinomycin A against Mycobacterium avium-Mycobacterium intracellulare complex after liposome encapsulation.

Authors:  R Gomez-Flores; R Hsia; R Tamez-Guerra; R T Mehta
Journal:  Antimicrob Agents Chemother       Date:  1996-11       Impact factor: 5.191

3.  Reduction of no synthase expression and tumor necrosis factor alpha production in macrophages by amphotericin B lipid carriers.

Authors:  M Larabi; P Legrand; M Appel; S Gil; M Lepoivre; J Devissaguet; F Puisieux; G Barratt
Journal:  Antimicrob Agents Chemother       Date:  2001-02       Impact factor: 5.191

4.  Pharmacokinetics and pharmacodynamics of amphotericin B deoxycholate, liposomal amphotericin B, and amphotericin B lipid complex in an in vitro model of invasive pulmonary aspergillosis.

Authors:  Jodi M Lestner; Susan J Howard; Joanne Goodwin; Lea Gregson; Jayesh Majithiya; Thomas J Walsh; Gerard M Jensen; William W Hope
Journal:  Antimicrob Agents Chemother       Date:  2010-05-03       Impact factor: 5.191

Review 5.  Carrier effects on biological activity of amphotericin B.

Authors:  J Brajtburg; J Bolard
Journal:  Clin Microbiol Rev       Date:  1996-10       Impact factor: 26.132

Review 6.  Nanoparticle approaches against bacterial infections.

Authors:  Weiwei Gao; Soracha Thamphiwatana; Pavimol Angsantikul; Liangfang Zhang
Journal:  Wiley Interdiscip Rev Nanomed Nanobiotechnol       Date:  2014-07-15

Review 7.  Diversity of lipid-based polyene formulations and their behavior in biological systems.

Authors:  K M Wasan; G Lopez-Berestein
Journal:  Eur J Clin Microbiol Infect Dis       Date:  1997-01       Impact factor: 3.267

Review 8.  Biopharmaceutical aspects of lipid formulations of amphotericin B.

Authors:  G Storm; E van Etten
Journal:  Eur J Clin Microbiol Infect Dis       Date:  1997-01       Impact factor: 3.267

9.  Evaluation of renal toxicity and antifungal activity of free and liposomal amphotericin B following a single intravenous dose to diabetic rats with systemic candidiasis.

Authors:  K M Wasan; J S Conklin
Journal:  Antimicrob Agents Chemother       Date:  1996-08       Impact factor: 5.191

10.  Liposome encapsulation of clofazimine reduces toxicity in vitro and in vivo and improves therapeutic efficacy in the beige mouse model of disseminated Mycobacterium avium-M. intracellulare complex infection.

Authors:  R T Mehta
Journal:  Antimicrob Agents Chemother       Date:  1996-08       Impact factor: 5.191

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.